NO20084452L - Intranasal influensavaksine basert pa virosomer - Google Patents
Intranasal influensavaksine basert pa virosomerInfo
- Publication number
- NO20084452L NO20084452L NO20084452A NO20084452A NO20084452L NO 20084452 L NO20084452 L NO 20084452L NO 20084452 A NO20084452 A NO 20084452A NO 20084452 A NO20084452 A NO 20084452A NO 20084452 L NO20084452 L NO 20084452L
- Authority
- NO
- Norway
- Prior art keywords
- composition
- virosomes
- influenza
- reconstituted
- inhalation administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Sammendrag Den foreliggende oppfinnelsen tilveiebringer en sammensetning av influensavirosomer som omfatter rekonstituerte konvolutter av nevnte virus, hvor de virale konvoluttene er fullstendig utledet fra influensavirale partikler, hvor ingen lipid er tilsatt fra en ekstern kilde til de rekonstituerte virosomene, hvor virosomene omfatter influensaantigenene hemagglutinin og/eller neuraminidase eller derivater av dem, hvor ingen separat adjuvans og/eller immunstimulator er tilsatt til sammensetningen og hvor sammensetningen er for intranasal eller inhaleringsadministrering hvis sammensetning er karakterisert ved at en enkel intranasal eller inhaleringsadministrering til et menneske er tilstrekkelig for induksjonen av en systemisk immunrespons og/eller en lokal immunrespons og/eller en sytotoksisk lymfosyttrespons mot nevnte influensaantigen, hvis systemisk respons er i overensstemmelse med CHMP kriteriene for influensavaksinen og hvor dosen for hemagglutinin per viral stamme per intranasal eller inhaleringsadministrering er lavere enn eller lik 30 µg. Oppfinnelsen tilveiebringer også anvendelsen av rekonstituerte influensavirosomer for produksjonen av nevnte sammensetning og følgelig produserte vaksineformuleringer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78446206P | 2006-03-22 | 2006-03-22 | |
EP06111534 | 2006-03-22 | ||
PCT/EP2007/052690 WO2007107585A1 (en) | 2006-03-22 | 2007-03-21 | Intranasal influenza vaccine based on virosomes |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20084452L true NO20084452L (no) | 2008-10-22 |
Family
ID=38038698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20084452A NO20084452L (no) | 2006-03-22 | 2008-10-22 | Intranasal influensavaksine basert pa virosomer |
Country Status (21)
Country | Link |
---|---|
EP (2) | EP2158921B1 (no) |
JP (1) | JP5285595B2 (no) |
KR (1) | KR20090016659A (no) |
AR (1) | AR059972A1 (no) |
AT (2) | ATE539766T1 (no) |
AU (1) | AU2007228736B2 (no) |
BR (1) | BRPI0709864A2 (no) |
CA (1) | CA2646895A1 (no) |
DE (1) | DE602007003815D1 (no) |
DK (2) | DK1996229T3 (no) |
EA (1) | EA014532B1 (no) |
ES (2) | ES2338382T3 (no) |
HR (2) | HRP20100144T1 (no) |
IL (1) | IL193840A (no) |
MY (1) | MY142996A (no) |
NO (1) | NO20084452L (no) |
PL (2) | PL1996229T3 (no) |
PT (2) | PT2158921E (no) |
SA (1) | SA07280116B1 (no) |
SI (2) | SI1996229T1 (no) |
WO (1) | WO2007107585A1 (no) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2011107757A (ru) * | 2008-08-01 | 2012-09-10 | Гамма Ваксинс Пти Лимитед (Au) | Вакцины против гриппа |
KR20130140050A (ko) * | 2010-11-02 | 2013-12-23 | 헥토 마뉴엘 제페다 로페즈 | A/h1n1 범유행 인플루엔자 바이러스에 대한 신규한 백신 |
US11523988B2 (en) | 2018-11-29 | 2022-12-13 | Catalent U.K. Swindon Zydis Limited | Oral dispersible vaccine comprising virosomes |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9018690D0 (en) * | 1990-08-24 | 1990-10-10 | Wellcome Found | Vaccines |
EP1447080A1 (en) * | 2003-02-13 | 2004-08-18 | Bestewil Holding B.V. | Method for producing virosome-like particles |
AR056245A1 (es) * | 2003-06-19 | 2007-10-03 | Bestewil Holding Bv | Membranas virales reconstituidas funcionales que contienen un coadyuvante |
-
2007
- 2007-03-20 AR ARP070101114A patent/AR059972A1/es not_active Application Discontinuation
- 2007-03-21 AT AT09178084T patent/ATE539766T1/de active
- 2007-03-21 PT PT09178084T patent/PT2158921E/pt unknown
- 2007-03-21 KR KR1020087025693A patent/KR20090016659A/ko not_active Application Discontinuation
- 2007-03-21 JP JP2009500864A patent/JP5285595B2/ja not_active Expired - Fee Related
- 2007-03-21 EA EA200870361A patent/EA014532B1/ru not_active IP Right Cessation
- 2007-03-21 SI SI200730184T patent/SI1996229T1/sl unknown
- 2007-03-21 PT PT07727166T patent/PT1996229E/pt unknown
- 2007-03-21 EP EP09178084A patent/EP2158921B1/en active Active
- 2007-03-21 WO PCT/EP2007/052690 patent/WO2007107585A1/en active Application Filing
- 2007-03-21 DE DE602007003815T patent/DE602007003815D1/de active Active
- 2007-03-21 MY MYPI20083534A patent/MY142996A/en unknown
- 2007-03-21 AT AT07727166T patent/ATE451931T1/de active
- 2007-03-21 BR BRPI0709864-2A patent/BRPI0709864A2/pt not_active IP Right Cessation
- 2007-03-21 EP EP07727166A patent/EP1996229B1/en active Active
- 2007-03-21 DK DK07727166.6T patent/DK1996229T3/da active
- 2007-03-21 DK DK09178084.1T patent/DK2158921T3/da active
- 2007-03-21 ES ES07727166T patent/ES2338382T3/es active Active
- 2007-03-21 AU AU2007228736A patent/AU2007228736B2/en not_active Ceased
- 2007-03-21 SI SI200730842T patent/SI2158921T1/sl unknown
- 2007-03-21 ES ES09178084T patent/ES2375436T3/es active Active
- 2007-03-21 SA SA07280116A patent/SA07280116B1/ar unknown
- 2007-03-21 PL PL07727166T patent/PL1996229T3/pl unknown
- 2007-03-21 PL PL09178084T patent/PL2158921T3/pl unknown
- 2007-03-21 CA CA002646895A patent/CA2646895A1/en not_active Abandoned
-
2008
- 2008-09-02 IL IL193840A patent/IL193840A/en not_active IP Right Cessation
- 2008-10-22 NO NO20084452A patent/NO20084452L/no not_active Application Discontinuation
-
2010
- 2010-03-12 HR HR20100144T patent/HRP20100144T1/hr unknown
-
2012
- 2012-01-05 HR HR20120013T patent/HRP20120013T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Quiñones-Parra et al. | Universal immunity to influenza must outwit immune evasion | |
Deliyannis et al. | Intranasal lipopeptide primes lung‐resident memory CD8+ T cells for long‐term pulmonary protection against influenza | |
Sambhara et al. | Heterosubtypic Immunity against Human Influenza A Viruses, Including Recently Emerged Avian H5 and H9 Viruses, Induced by FLU–ISCOM Vaccine in Mice Requires both Cytotoxic T-Lymphocyte and Macrophage Function | |
Kreijtz et al. | Immune responses to influenza virus infection | |
Rimmelzwaan et al. | Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development | |
Kamijuku et al. | Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses | |
Johansson et al. | Changing perspective on immunization against influenza | |
Geeraedts et al. | Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs | |
Ghendon et al. | Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines | |
Jelley-Gibbs et al. | Persistent depots of influenza antigen fail to induce a cytotoxic CD8 T cell response | |
DE60024112D1 (de) | Influenzavirus-impfstoffzusammensetzung | |
EA023662B1 (ru) | Вакцины против гриппа со сниженным количеством сквалена | |
Budimir et al. | Heterosubtypic cross‐protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration | |
AU2011280259A8 (en) | Influenza vaccine | |
BR112015017966A2 (pt) | composições imunogênicas compreendendo vírus silificado e métodos de uso | |
NO20084452L (no) | Intranasal influensavaksine basert pa virosomer | |
Stambas et al. | Killer T cells in influenza | |
BR112014011345A2 (pt) | partículas tipo vírus da influenza (vlps) compreendendo nicotiana tabacum produzida por hemaglutinina | |
WO2006045532A3 (en) | Virosome particles comprising antigens from influenza virus and hepatitis b virus | |
Jones et al. | A nasal Proteosome™ influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity | |
Zhang et al. | Broadly protective CD8+ T cell immunity to highly conserved epitopes elicited by heat shock protein gp96-adjuvanted influenza monovalent split vaccine | |
van de Sandt et al. | Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine | |
Bhatnagar et al. | Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice | |
WO2006062637A3 (en) | Influenza vaccination | |
Cao et al. | Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: ABBOTT BIOLOGICALS BV, NL |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |